Option auswählen
Hersteller Händler

sphingotec GmbH

Neuendorfstr. 15A, 16761 Hennigsdorf
Telefon +49 3302 20565-0
Fax +49 3302 20565-55

Dieser Aussteller ist Mitaussteller von
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg e.V.


MEDICA 2019 Hallenplan (Halle 3): Stand G52


MEDICA 2019 Geländeplan: Halle 3


Michał Bagrowski

Senior Distribution Manager

+49 173 130 87 98


Unser Angebot


  • 03  Diagnostika
  • 03.02  Immunochemie / Immunologie
  • 03.02.02  Diagnose-Schnelltests


Über uns


SphingoTec GmbH (“sphingotec”; Hennigsdorf by Berlin, Germany) develops and markets innovative in-vitro diagnostic tests (IVD) for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. sphingotec’s assay portfolio includes sphingotest® bio-ADM® the assay for bioactive adrenomedullin, a unique biomarker for real-time assessment of vascular integrity in conditions like sepsis or congestive heart failure, sphingotest® penKid®, the assay for proenkephalin, a unique biomarker for real-time assessment of kidney function and sphingotest® DPP3, an assay for Dipeptidyl Peptidase 3, a unique biomarker for signalling pathway disruptions leading to acute organ dysfunction. Along with the Nexus IB10 POC platform by its subsidiary Nexus Dx Inc. (San Diego, CA, USA) acquired from Samsung in 2018, sphingotec markets a standard marker portfolio for acute care. In addition, sphingotec developed a portfolio of novel biomarkers, which predict the risks of obesity, breast cancer and cardiovascular diseases.

Mehr Weniger